Estados financieros detallados de Ligand Pharmaceuticals Incorporated (LGND): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Ligand Pharmaceuticals Incorporated registró ingresos de $268.1M en el último ejercicio fiscal, con un CAGR de 5 años del 10.4%.
Márgenes de los últimos 12 meses: margen bruto 98.6%, margen operativo 34.7%, margen neto 67.9%. El flujo de caja libre creció a un CAGR del -0.5% en 5 años.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $109.0M | $141.1M | $251.5M | $120.3M | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| Coste de Ventas | $5.6M | $5.4M | $6.3M | $11.3M | $30.4M | $62.2M | $52.8M | $35.0M | $11.1M | $6.6M |
| Beneficio Bruto | $103.4M | $135.7M | $245.1M | $108.9M | $133.1M | $179.4M | $143.4M | $96.3M | $156.1M | $261.5M |
| I+D | $21.2M | $26.9M | $27.9M | $55.9M | $40.5M | $32.1M | $36.1M | $24.5M | $21.4M | $81.2M |
| Generales y Administrativos | $26.6M | $28.7M | $37.7M | $41.9M | $60.0M | $46.8M | $70.1M | $52.8M | $78.7M | $92.4M |
| Gastos Operativos | $58.5M | $67.7M | $81.4M | -$698.1M | $95.6M | $75.5M | $140.4M | $84.3M | $178.7M | $214.3M |
| Beneficio Operativo | $43.9M | $68.1M | $163.7M | $807.1M | $37.5M | $103.9M | $3.0M | $11.9M | -$22.6M | $47.2M |
| EBITDA | $55.2M | $81.2M | $238.3M | $876.1M | $56.7M | $142.8M | $81.2M | $100.8M | $40.8M | $192.7M |
| Gastos por Intereses | $12.2M | $11.4M | $48.3M | $35.7M | $27.4M | $19.6M | $1.8M | $656000 | $3.0M | $4.7M |
| Beneficio Antes de Impuestos | $8.0M | $57.2M | $173.3M | $796.6M | $1.3M | $72.2M | $36.0M | $63.7M | $2.5M | $159.0M |
| Impuestos | $10.3M | $44.7M | $30.0M | $167.3M | -$5.3M | -$4.1M | $41.2M | $9.8M | $6.5M | $34.5M |
| Beneficio Neto | -$1.6M | $12.6M | $143.3M | $629.3M | -$3.0M | $57.1M | -$33.4M | $52.2M | -$4.0M | $124.5M |
| BPA | $-0.08 | $0.60 | $5.96 | $33.13 | $-0.18 | $3.46 | $-1.98 | $3.02 | $-0.22 | $6.44 |
| BPA Diluido | $-0.08 | $0.53 | $5.96 | $31.85 | $-0.18 | $3.34 | $-1.98 | $2.94 | $-0.22 | $6.13 |
| Acciones en Circulación (Diluidas) | $20.8M | $23.5M | $24.1M | $19.8M | $16.2M | $17.2M | $16.9M | $17.8M | $18.3M | $20.3M |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $141.0M | $201.7M | $718.4M | $71.5M | $47.6M | $19.5M | $45.0M | $23.0M | $72.3M | $174.9M |
| Inversiones a Corto | 0 | 0 | $46.2M | $998.3M | $363.6M | $321.6M | $166.9M | $147.4M | $183.9M | $558.6M |
| Cuentas por Cobrar | $18.2M | $25.6M | $55.9M | $41.7M | $59.1M | $91.6M | $35.0M | $39.3M | $42.4M | $61.0M |
| Inventario | $1.9M | $4.4M | $7.1M | $7.3M | $26.5M | $27.3M | $13.3M | $24.0M | $14.1M | $9.1M |
| Activos Corrientes | $163.1M | $237.0M | $870.5M | $1.12B | $500.6M | $464.8M | $263.6M | $237.4M | $331.6M | $832.3M |
| Inmovilizado Material | $1.8M | $4.2M | $5.4M | $17.6M | $37.2M | $32.6M | $27.5M | $25.1M | $24.8M | $10.8M |
| Fondo de Comercio | $276.9M | $314.5M | $306.4M | $95.2M | $189.7M | $105.7M | $105.7M | $103.4M | $105.2M | $101.5M |
| Activos Intangibles | $25.8M | $19.5M | $31.5M | $230.5M | $606.3M | $386.8M | $352.6M | $299.6M | $266.6M | $422.3M |
| Activos Totales | $601.6M | $671.0M | $1.26B | $1.49B | $1.36B | $1.30B | $762.7M | $787.2M | $941.8M | $1.56B |
| Cuentas por Pagar | $2.7M | $2.3M | $4.2M | $2.4M | $3.8M | $8.4M | $5.3M | $2.4M | $5.2M | $3.2M |
| Deuda a Corto | $212.9M | $224.5M | $26.4M | 0 | 0 | 0 | $76.7M | 0 | 0 | 0 |
| Pasivos Corrientes | $227.1M | $238.9M | $82.2M | $17.0M | $100.1M | $41.7M | $98.8M | $16.8M | $37.1M | $37.4M |
| Deuda a Largo | $29.6M | $18.9M | $609.9M | $639.0M | $442.3M | $320.7M | 0 | 0 | 0 | $446.2M |
| Pasivos Totales | $230.7M | $252.4M | $699.9M | $727.7M | $652.8M | $476.4M | $165.2M | $86.3M | $111.3M | $543.4M |
| Reservas | -$431.1M | -$400.9M | -$229.2M | $400.1M | $392.0M | $449.1M | $450.9M | $503.0M | $499.0M | $608.1M |
| Patrimonio Neto | $370.9M | $418.6M | $560.9M | $767.2M | $709.5M | $821.2M | $597.5M | $700.9M | $830.4M | $1.02B |
| Deuda Total | $212.9M | $224.5M | $636.3M | $650.2M | $456.4M | $324.4M | $87.7M | $6.2M | $7.1M | $451.5M |
| Deuda Neta | $71.9M | $22.9M | -$128.3M | -$419.7M | $45.2M | -$16.7M | -$124.1M | -$164.1M | -$249.1M | -$282.0M |
| Capital Circulante | -$64.1M | -$1.8M | $788.3M | $1.11B | $400.4M | $423.1M | $164.8M | $220.6M | $294.4M | $794.8M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$2.4M | $12.6M | $143.3M | $629.3M | -$3.0M | $57.1M | -$33.4M | $52.2M | -$4.0M | $124.5M |
| Amortizaciones | $11.3M | $11.7M | $14.7M | $43.7M | $28.0M | $50.9M | $51.4M | $36.5M | $35.2M | $35.7M |
| Compensación en Acciones | $18.9M | $24.9M | $20.8M | $24.5M | $30.7M | $38.8M | $60.3M | $25.7M | $41.1M | 0 |
| Cambio en Capital Circulante | -$10.6M | -$11.4M | -$38.9M | -$4.2M | -$10.1M | -$52.2M | $65.7M | -$34.4M | $19.4M | -$12.7M |
| Flujo de Caja Operativo | $63.0M | $93.6M | $194.1M | -$29.3M | $54.6M | $78.8M | $137.8M | $49.6M | $97.0M | $49.4M |
| Inversiones (CapEx) | -$28.3M | -$7.2M | -$11.9M | -$2.6M | -$4.5M | -$8.8M | -$17.9M | -$53.8M | -$19.6M | -$452000 |
| Adquisiciones | -$94.2M | -$26.7M | -$5.9M | -$12.8M | -$383.3M | $494000 | -$750000 | -$25.7M | -$172.2M | -$8.1M |
| Recompra de Acciones | -$3.9M | -$2.0M | -$122.9M | -$453.0M | -$78.0M | -$18.4M | 0 | 0 | 0 | -$15.0M |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | $34.7M | $86.4M | $182.2M | -$31.9M | $50.1M | $70.0M | $119.9M | -$4.3M | $77.4M | $48.9M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +29.5% | +78.2% | -52.2% | +36.0% | +47.7% | -18.8% | -33.1% | +27.3% | +60.4% | |
| Crecimiento Beneficio Neto (anual) | +867.5% | +1041.5% | +339.1% | -100.5% | +2014.2% | -158.4% | +256.3% | -107.7% | +3186.6% | |
| Crecimiento BPA (anual) | +864.3% | +893.3% | +455.9% | -100.5% | +2022.2% | -157.2% | +252.5% | -107.3% | +3027.3% | |
| Cambio en Acciones (anual) | +12.7% | +2.5% | -17.9% | -18.1% | +6.6% | -2.2% | +5.3% | +3.0% | +11.0% | |
| Crecimiento FCF (anual) | +149.2% | +110.8% | -117.5% | +257.2% | +39.7% | +71.2% | -103.6% | +1912.0% | -36.8% | |
| Margen Bruto | 94.9% | 96.2% | 97.5% | 90.6% | 81.4% | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% |
| Margen Operativo | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 17.6% |
| Margen EBITDA | 50.6% | 57.5% | 94.8% | 728.4% | 34.6% | 59.1% | 41.4% | 76.8% | 24.4% | 71.9% |
| Margen Neto | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
| Margen FCF | 31.8% | 61.2% | 72.4% | -26.5% | 30.6% | 29.0% | 61.1% | -3.3% | 46.3% | 18.2% |
| Tasa Impositiva Efectiva | 129.7% | 78.1% | 17.3% | 21.0% | -410.7% | -5.7% | 114.5% | 15.5% | 260.1% | 21.7% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $1.66 | $3.68 | $7.57 | $-1.61 | $3.10 | $4.06 | $7.11 | $-0.24 | $4.23 | $2.41 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $20.8M | $21.0M | $24.0M | $19.0M | $16.2M | $16.6M | $16.9M | $17.3M | $18.3M | $19.3M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Margen bruto | 98.58% |
| Margen operativo | 34.74% |
| Margen neto | 67.88% |
Salud financiera
| Deuda / Patrimonio | 1.17 |
| Ratio corriente | 31.18 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -807.52 | 142.37 | 14.20 | 1.96 | -344.67 | 27.85 | -33.74 | 23.65 | -487.05 | 29.36 |
| P/VC | 3.56 | 4.29 | 3.63 | 1.61 | 1.42 | 1.95 | 1.89 | 1.76 | 2.36 | 3.59 |
| P/V | 12.12 | 12.73 | 8.10 | 10.27 | 6.14 | 6.63 | 5.74 | 9.41 | 11.73 | 13.64 |
| Margen Bruto | 94.9% | 96.2% | 97.5% | 90.6% | 81.4% | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% |
| Margen Operativo | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 17.6% |
| Margen Neto | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
Empresas relacionadas: ACAD · ADMA · BLTE · CRNX · DYN · MIRM · NAMS
Explorar sector: Healthcare · Biotechnology
Más secciones de LGND: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones